Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression...
Q2 2026
May 13, 2026
Q1 2026
Mar 16, 2026
FY 2025
Nov 12, 2025
Q4 2025
Q3 2025
Aug 13, 2025